Transfusion policy: when to stop the use of extremely rare blood for an allogeneic hematopoietic progenitor cell transplant recipient with a history of red cell alloimmunization.

about

A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation Optimizing the use of limited rare red cells for hematopoietic cell transplant recipients.

P2860

Q36941032-7E83E86F-4215-4426-AB98-D659433837CD Q50696780-A8A87594-B38C-4B93-AF45-E7469DEED562

P2860

Transfusion policy: when to stop the use of extremely rare blood for an allogeneic hematopoietic progenitor cell transplant recipient with a history of red cell alloimmunization.

Item

http://www.wikidata.org/entity/Q40218366

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Transfusion policy: when to st ...... of red cell alloimmunization.

@en

type

Item

label

Transfusion policy: when to st ...... of red cell alloimmunization.

@en

prefLabel

Transfusion policy: when to st ...... of red cell alloimmunization.

@en

P1476

Transfusion policy: when to st ...... of red cell alloimmunization.

@en

P2093

David Wuest

http://www.w3.org/2001/XMLSchema#string

Farid Boulad

http://www.w3.org/2001/XMLSchema#string

Lisa Senzel

http://www.w3.org/2001/XMLSchema#string

Marion E Reid

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.

Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation.

Evidence for ineffective erythropoiesis in severe sickle cell disease

Alloimmunization to RhD antigen in RhD-incompatible haemopoietic cell transplants with non-myeloablative conditioning.

Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation.

Long-term production of pre-existing alloantibodies to E and c after allogenic BMT in a patient with aplastic anemia resulting in delayed hemolytic anemia.

Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease.

Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia.

After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B.

ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation.

P304

781-787

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1537-2995.2007.01190.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17465941

http://www.w3.org/2001/XMLSchema#string

Transfusion policy: when to stop the use of extremely rare blood for an allogeneic hematopoietic progenitor cell transplant recipient with a history of red cell alloimmunization.

about

P2860

P2860

Transfusion policy: when to stop the use of extremely rare blood for an allogeneic hematopoietic progenitor cell transplant recipient with a history of red cell alloimmunization.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698